These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19228428)

  • 1. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
    Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
    Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
    Kew KM; Karner C; Mindus SM; Ferrara G
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD009019. PubMed ID: 24343671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
    Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
    Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
    Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
    COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
    Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
    Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
    Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
    Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
    Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
    N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results.
    Atienza T; Aquino T; Fernández M; Boonsawat W; Kawai M; Kudo T; Ekelund J; Ivanov S; Carlsson LG
    Respirology; 2013 Feb; 18(2):354-63. PubMed ID: 23126237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
    Cates CJ; Karner C
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007313. PubMed ID: 23633340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.
    D'Urzo A; Singh D; Garcia Gil E
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):13. PubMed ID: 28235977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.